Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes
NEJM Evidence · 28.11.2023 · 2 (12)
DOI: 10.1056/evidoa2300210 ↗Kurz gefasst
Fachartikel in der Zeitschrift NEJM Evidence, erschienen am 28.11.2023. Verfasst von Naim Shehadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptides, Glucosides. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rambam Health Care Campus, Haifa, Israel.
- Bar-Ilan University, Safed, Israel.
- University of Birmingham, Birmingham, United Kingdom.
- AstraZeneca, Gaithersburg, MD.
- AstraZeneca, Gothenburg, Sweden.
- Yale University, New Haven, CT.
Zitieren
APA
Shehadeh, N., Barrett, T., Galassetti, P., Karlsson, C., Monyak, J., Iqbal, N., & Tamborlane, W. V. (2023). Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes. NEJM Evidence, 2(12). https://doi.org/10.1056/evidoa2300210
Vancouver
Shehadeh N, Barrett T, Galassetti P, Karlsson C, Monyak J, Iqbal N, et al. Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes. NEJM Evidence. 2023;2(12). doi:10.1056/evidoa2300210
BibTeX
@article{Shehadeh2023,
author = {Shehadeh, Naim and Barrett, Timothy and Galassetti, Pietro and Karlsson, Cecilia and Monyak, John and Iqbal, Nayyar and Tamborlane, William V},
title = {Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes},
journal = {NEJM Evidence},
year = {2023},
volume = {2},
number = {12},
doi = {10.1056/evidoa2300210}
}
EUVIMED